Neogen Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Neogen Corporation (NASDAQ: NEOG) is set to release its third-quarter earnings before the market opens on Thursday, April 9. Analysts anticipate earnings of 5 cents per share on revenue of $204.62 million. Several analysts have recently updated their ratings and price targets for Neogen, with outcomes ranging from maintaining a Neutral rating to upgrading the stock.
Neogen’s Q3 Earnings Clouded by Regulatory Delays, Gross Margins Hold Strong
Neogen (NEOG) is projected to report Q3 2026 revenue of $215 million, a 4% year-over-year decline, with an expected net loss of $12 million due to regulatory scrutiny and delayed product approvals. Despite these headwinds and a downgraded rating from Jefferies, the company's gross margins remain strong, and Raymond James has upgraded Neogen to Market Outperformer due to robust demand in food safety diagnostics. Neogen is focusing on strategic expansion in Europe and R&D investment to mitigate regulatory challenges and diversify markets, offering cautious optimism for its longer-term prospects.
Countdown to Neogen (NEOG) Q3 Earnings: Wall Street Forecasts for Key Metrics
Wall Street analysts predict Neogen (NEOG) will report Q3 earnings of $0.04 per share, a 60% decline year-over-year, with revenues forecasted at $204.46 million, down 7.5%. The consensus EPS estimate has been revised downward by 8.3% in the last 30 days. Analysts have also provided detailed forecasts for various key metrics within Animal Safety and Food Safety divisions, with the stock currently holding a Zacks Rank #4 (Sell).
NEOG Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Neogen Corp (NEOG). It indicates a "Neutral" overall technical sentiment based on a proprietary analysis of 12 technical signals. The analysis details key indicators like RSI, MACD, support and resistance levels, and various moving averages to offer insights into NEOG's short-term momentum and long-term trends.
Neogen Leadership Change Puts Governance And Compliance Execution In Focus
Neogen (NasdaqGS:NEOG) has announced the departure of its Chief Legal and Administrative Officer, Amy Rocklin, effective March 31, 2026. This leadership change is significant due to Neogen's recent performance fluctuations and ongoing issues like labor actions and product quality concerns. Investors are advised to monitor the company's succession plan, shifts in compliance priorities, and how the board communicates around this transition, especially given the company's current unprofitability and integration challenges.
Neogen (NEOG) to Release Quarterly Earnings on Wednesday
Neogen (NASDAQ:NEOG) is scheduled to release its Q3 2026 earnings before the market opens on Wednesday, April 8th, with analysts forecasting an EPS of $0.04 and revenue of $204.615 million. The company's previous report showed an EPS beat but a negative net margin and a year-over-year revenue decline. The stock currently holds a consensus "Hold" rating with a target price of $10.67, and institutional investors own a significant portion of its shares.
Neogen Corporation Announces Departure of Chief Legal and Administrative Officer Amy Rocklin Effective March 31, 2026
Neogen Corporation (Nasdaq: NEOG) announced that its Chief Legal and Administrative Officer, Amy Rocklin, will depart the company effective March 31, 2026. This high-level executive change may lead to short-term stock volatility and prompts investor scrutiny regarding succession planning and potential shifts in company direction. Investors are advised to monitor further announcements for clarity on leadership transition.
Legal chief exits Neogen (NASDAQ: NEOG) effective March 31, 2026
Neogen Corporation announced that its Chief Legal and Administrative Officer, Amy Rocklin, will depart the company effective March 31, 2026. This leadership change was reported via an 8-K filing on March 30, 2026. The filing confirms that R. Bryan Riggsbee, the Chief Financial Officer, signed the report on behalf of Neogen.
Amy Rocklin to Leave Neogen as Chief Legal and Administrative Officer
Neogen (NEOG) announced that Amy Rocklin, its Chief Legal and Administrative Officer, will depart from the company on March 31, 2026. The reason for her departure was not disclosed, and no information about a replacement or background details was provided in the announcement which originated from an SEC filing.
Neogen Corporation announces departure of chief legal and administrative officer
Neogen Corporation announced the departure of its Chief Legal and Administrative Officer, Amy Rocklin, effective March 31, 2026. This news follows a period of strategic activity for Neogen, including exceeding fiscal second-quarter earnings expectations, raising guidance, and entering an agreement to sell its animal genomics business to Zoetis Inc. for $160 million. The company is based in Lansing, Michigan, and is listed on the Nasdaq Global Select Market.
SG Americas Securities LLC Purchases 1,460,488 Shares of Neogen Corporation $NEOG
SG Americas Securities LLC significantly increased its stake in Neogen Corporation by 929.6% in Q4, acquiring 1,460,488 shares, bringing its total holding to 1,617,597 shares valued at $11.31 million. Neogen, despite beating Q4 revenue and EPS estimates, remains unprofitable and has mixed analyst ratings. The stock's institutional ownership is high at 96.73%, and several other institutional investors also adjusted their positions.
Neogen Corporation $NEOG Shares Acquired by JPMorgan Chase & Co.
JPMorgan Chase & Co. increased its stake in Neogen Corporation ($NEOG) by 19.9% in Q3, acquiring an additional 278,886 shares, bringing its total holding to 1,680,212 shares valued at $9.59 million. The stock maintains a "Hold" consensus rating from analysts, with a target price of $10.67, and recently reported an EPS beat with $224.7 million in revenue. Neogen, a global provider of food and animal safety products, currently trades with a market capitalization of $1.89 billion.
Vanguard realignment leads to separate reporting; 0 NEOG shares (NEOG)
The Vanguard Group filed an Amendment No. 15 to a Schedule 13G/A, reporting 0 shares of Neogen Corp, representing 0% beneficial ownership, due to an internal realignment on January 12, 2026. This realignment, under SEC Release No. 34-39538, caused certain Vanguard subsidiaries and business divisions to begin reporting their holdings separately. Consequently, The Vanguard Group, Inc. no longer beneficially owns the securities reported by these newly disaggregated entities, though the subsidiaries continue to pursue the same investment strategies.
Enovis, Neogen, Humana, LifeStance Health Group, and Hims & Hers Health Stocks Trade Down, What You Need To Know
Several healthcare stocks, including Enovis, Neogen, Humana, LifeStance Health Group, and Hims & Hers Health, traded down in the afternoon session due to escalating uncertainty from the U.S.-Iran conflict and policy deadlines. The market's dislike for unpredictability, coupled with a decline in consumer confidence, led to a general market downturn. Despite a recent surge due to a collaboration with Novo Nordisk, Hims & Hers Health has seen significant volatility and a year-to-date decline.
Neogen Corp. Stock Hits Day Low of $8.24 Amid Price Pressure
Neogen Corp. experienced significant stock volatility, with a 9.82% decline today to an intraday low of $8.24, and a 15.21% drop over the past week. Despite underperforming the S&P 500 over three years, the company shows a positive year-to-date return of 19.6% and healthy long-term net sales growth of 15.23%. Neogen maintains a low debt-to-equity ratio and reported a net profit of $26.68 million in its latest half-year results.
Neogen Corp. Opens Weak with 6.15% Gap Down Amid Market Concerns
Neogen Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, experienced a 6.15% gap down at market open, contributing to a 9.82% daily decline and a 25.02% decrease over the past month. Despite mixed technical indicators, including mildly bearish weekly MACD and bullish monthly MACD, the company has a market capitalization of USD 1,982 million and a P/E ratio of 150.00. The article highlights the company's financial metrics such as a 0.31 debt-to-equity ratio and a 0.63% return on equity.
Neogen Corporation (NASDAQ:NEOG) Receives Average Rating of "Hold" from Brokerages
Neogen Corporation (NASDAQ:NEOG) has received a consensus "Hold" rating from six brokerages, with an average 1-year price target of $10.67. The company's shares opened at $8.36 and were trading down approximately 3.9%, despite an EPS and revenue beat for the quarter, though revenue decreased 2.9% year-over-year. Institutional ownership in Neogen is notably high at 96.73%, with several major institutions increasing or initiating positions in the fourth quarter.
Hudson Bay Capital Management LP Invests $28.55 Million in Neogen Corporation $NEOG
Hudson Bay Capital Management LP has invested $28.55 million in Neogen Corporation by acquiring 5,000,000 shares, now owning approximately 2.30% of the company, with institutional investors holding 96.73% of the stock. Analysts currently rate Neogen as "Hold" with a consensus target of $10.67, despite the company recently beating earnings expectations but reporting a significant negative net margin and a decline in year-over-year revenue.
ArrowMark Colorado Holdings LLC Grows Stock Holdings in Neogen Corporation $NEOG
ArrowMark Colorado Holdings LLC increased its stake in Neogen Corporation by 28.5% in the third quarter, holding over 1.1 million shares. Other institutional investors also bought into Neogen, with 96.73% of the stock owned by hedge funds and institutions. The company has received mixed analyst ratings, with an average "Hold" and a target price of $10.67, and recently reported quarterly earnings that topped analyst expectations.
Neogen Corp Stock (ISIN: US6404911066) Faces Headwinds in Food Safety Sector Amid Regulatory Shifts
Neogen Corp, a key player in food safety and biosecurity testing, is facing challenges due to evolving regulations and market pressures, particularly in its diagnostics segment. Despite strong recurrent revenue from consumables and a solid balance sheet, the company's stock is under pressure from broader biotech sector rotation and rising input costs. European investors are monitoring Neogen for its defensive qualities, its alignment with EU regulatory standards, and its potential for operating leverage in a cautious market.
Neogen Corp. Hits Day Low of $9.63 Amid Price Pressure
Neogen Corp., a small-cap pharmaceutical and biotechnology company, experienced significant stock volatility, with its stock declining by 9.26% to an intraday low of USD 9.63. Despite underperforming against the S&P 500 over various periods, the company maintains a low debt-to-equity ratio, healthy long-term net sales growth, and strong institutional holdings.
Clarkston Capital Partners LLC Has $66.77 Million Position in Neogen Corporation $NEOG
Clarkston Capital Partners LLC has reduced its stake in Neogen Corporation by 16.5% during Q3, now holding 11,693,250 shares valued at approximately $66.77 million, making it their 24th largest holding. Despite this, Neogen has seen other institutional investors increase their positions, with institutional ownership nearing 96.73%. Analysts maintain a "Hold" consensus with an average price target of $10.67, even after the company beat revenue and EPS estimates in its latest quarter but saw its stock trade down 9.3%.
Teton Advisors LLC Makes New Investment in Neogen Corporation $NEOG
Teton Advisors LLC has made a new investment in Neogen Corporation (NASDAQ:NEOG), purchasing 186,160 shares valued at approximately $1.06 million in Q3. Institutional investors now own 96.73% of Neogen, a company that recently beat EPS and revenue estimates but experienced a 2.9% year-over-year revenue decline and a deeply negative net margin, causing its stock to drop. Analyst sentiment is mixed, with a consensus "Hold" rating and an average target price of $10.67.
JPMorgan Chase & Co. Purchases 278,886 Shares of Neogen Corporation $NEOG
JPMorgan Chase & Co. has increased its holdings in Neogen Corporation by 19.9%, purchasing an additional 278,886 shares to now own 1,680,212 shares valued at approximately $9.59 million. Despite a mixed analyst consensus of "Hold" with a price target of $10.67, Neogen recently surpassed earnings expectations with $0.10 EPS on $224.7 million revenue. The company, which specializes in food and animal safety products, is currently trading near $9.70 with a market capitalization of $2.11 billion.
Option Care Health, CooperCompanies, Neogen, GoodRx, and Fortrea Shares Are Falling, What You Need To Know
Shares of Option Care Health (OPCH), CooperCompanies (COO), Neogen (NEOG), GoodRx (GDRX), and Fortrea (FTRE) fell following a surprising contraction in February employment, including significant job losses in the healthcare sector. This economic data has raised concerns among investors about decreased healthcare spending and service demand, impacting the sector's market performance. Despite the general downturn, Neogen previously surpassed Q4 expectations and raised its full-year guidance, though its shares remain below their 52-week high.
Zoetis to acquire Neogen Corp. genomics business
Zoetis Inc. is set to acquire Neogen Corp.'s animal genomics business for $160 million, with the deal expected to close in the second half of 2026. Neogen, a leader in U.S. beef and dairy genomics, plans to use the proceeds for debt reduction and to focus on its core food and animal safety businesses. This acquisition aligns with Zoetis' strategy to expand its Precision Animal Health business and enhance livestock innovation through genomics.
Quantbot Technologies LP Buys 110,145 Shares of Neogen Corporation $NEOG
Quantbot Technologies LP has increased its holdings in Neogen Corporation (NASDAQ:NEOG) by 45.7%, now owning 351,101 shares valued at approximately $2.005 million. Despite analysts having a mixed consensus rating of "Hold" with a target price of $10.67, Neogen recently beat quarterly earnings and revenue estimates but sustained a negative net margin. Other institutional investors like Savant Capital, Cresset Asset Management, and Osaic Holdings Inc. also bought into Neogen.
Vanguard Group Inc. Acquires 385,885 Shares of Neogen Corporation $NEOG
Vanguard Group Inc. increased its stake in Neogen Corporation by 1.6% in the third quarter, acquiring 385,885 additional shares, bringing its total ownership to 23,963,223 shares valued at approximately $136.83 million. Institutional investors collectively hold 96.73% of the company's stock. Neogen recently surpassed earnings and revenue estimates for its latest quarter, reporting $0.10 EPS and $224.7 million in revenue.
Zoetis to acquire Neogen animal genomics business for $160M
Zoetis Inc., an animal health company based in Parsippany, has agreed to acquire Neogen Corp.'s animal genomics business for $160 million. This acquisition will enhance Zoetis' Precision Animal Health portfolio and support its strategy to advance livestock innovation. The deal is expected to close in the second half of 2026, subject to regulatory approvals.
Lansing-based Neogen sells genomics business to Zoetis
Neogen, a Lansing-based company, has announced the sale of its genomics business to Zoetis. This transaction marks a significant development for both companies, impacting their respective operations in the genomics sector. Further details regarding the terms of the sale were not immediately available.
Zoetis to acquire Neogen’s animal genomics business for $160M
Zoetis Inc. is set to acquire Neogen Corp.'s animal genomics business for $160 million, a move that will bolster Zoetis' Precision Animal Health portfolio. The acquisition will expand Zoetis' capabilities in delivering predictive insights and individualized care to livestock producers and companion animal owners globally. Neogen's genomics business, which operates in over 120 countries, offers advanced genotyping and sequencing technologies to provide data-driven decisions for animal health and productivity.
Neogen To Sell Genomics Business To Zoetis
Neogen Corp. has announced its agreement to sell its global genomics business to Zoetis for $160 million. This divestiture aligns with Neogen's strategy to simplify its business and focus on core markets, with the proceeds primarily intended for debt reduction. The transaction is expected to close by the end of Neogen's first half of fiscal year 2027, subject to regulatory approvals.
Neogen To Sell Genomics Business To Zoetis For $160 Mln
Neogen Corporation announced its agreement to sell its genomics business to Zoetis Inc. for $160 million. This divestiture aims to simplify Neogen's business and focus on core strategic markets, with the net proceeds primarily allocated to debt reduction. The genomics business generated approximately $90 million in sales in fiscal year 2025.
Zoetis to Acquire Neogen’s Animal Genomics Business
Zoetis Inc., the global leader in animal health, has announced its acquisition of Neogen Corporation’s animal genomics business for $160 million. This strategic move aims to enhance Zoetis' precision animal health portfolio by integrating Neogen’s extensive global genomics capabilities, offering predictive insights and individualized care for livestock and companion animals worldwide. Neogen's divestiture is part of its strategy to simplify its business and focus on core markets, while Zoetis plans to leverage this acquisition to further innovate in genomics and strengthen its commitment to livestock producers.
Neogen Corporation $NEOG Shares Sold by William Blair Investment Management LLC
William Blair Investment Management LLC significantly reduced its stake in Neogen Corporation by 37.2% in the third quarter, selling nearly 3.5 million shares. Despite exceeding quarterly EPS and revenue estimates, Neogen reported a negative net margin of 68.47% and a year-over-year revenue decrease. The stock currently holds a consensus "Hold" rating from analysts with a target price of $10.67.
Neogen sheds $90M genomics unit in $160M Zoetis deal to cut debt
Neogen Corporation announced its definitive agreement to sell its global genomics business to Zoetis Inc. for $160 million. This divestiture, part of Neogen's portfolio review, aims to accelerate debt reduction and enhance profitability by focusing on core food and animal safety markets. The transaction is expected to close by the end of Neogen's first half of the 2027 fiscal year, pending regulatory approval.
DNA tests for farm animals: Zoetis pays $160M for Neogen unit
Zoetis Inc. announced a definitive agreement to acquire Neogen Corporation's animal genomics business for $160 million. This acquisition is set to expand Zoetis's Precision Animal Health portfolio by integrating Neogen's genomic technologies and data solutions, offering predictive insights and individualized care for livestock and companion animals. The deal strengthens Zoetis's commitment to innovation in animal health and is expected to close in the second half of 2026.
Neogen Corp. Hits New 52-Week High of $11.43, Signaling Recovery
Neogen Corp. has reached a new 52-week high of $11.43, recovering significantly from its low of $3.87, despite a 30.03% decline over the past year. The company, a small-cap player in the Pharmaceuticals & Biotechnology sector, maintains a market capitalization of $2,465 million. Its financial metrics include a P/E ratio of 31.00, return on equity of 0.63%, and a stable debt-to-equity ratio of 0.31.
Neogen Corporation (NASDAQ:NEOG) Receives Average Recommendation of "Hold" from Brokerages
Neogen Corporation (NASDAQ:NEOG) has received a consensus "Hold" rating from six brokerages, with an average 12-month price objective of $10.67. The company recently reported quarterly earnings of $0.10 EPS on $224.69 million in revenue, beating analyst estimates. Institutional investors hold a significant 96.73% stake in Neogen, with several firms increasing their positions.
NEOG Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Neogen Corp (NEOG), including its income statement, balance sheet, and cash flow statement. It highlights the company's financial health signals, key metrics, and financial ratios, covering profitability, growth, leverage, liquidity, and cash flow up to fiscal year 2025. The analysis reveals significant decreases in revenue, net income, and EPS, resulting in a weak Piotroski F-Score and mixed earnings quality.
Neogen Corporation stock hits 52-week high at 11.4 USD
Neogen Corporation's stock reached a new 52-week high of $11.40, following a robust performance with a 100% surge in the last six months and a 61% year-to-date gain. Despite being considered overvalued by InvestingPro, the company recently surpassed earnings expectations for Q2 FY2026 and raised guidance, leading to positive analyst revisions and increased price targets.
Q4 Medical Devices & Supplies - Diversified Earnings: Neogen (NASDAQ:NEOG) Impresses
Neogen (NASDAQ:NEOG) delivered impressive Q4 earnings, with revenues of $224.7 million beating analyst expectations by 7.2%, though revenue was down 2.8% year-on-year. The medical devices industry generally saw mixed Q4 results, but Neogen's strong performance led to a significant 53.2% stock price increase since reporting, while companies like Abbott Laboratories and Boston Scientific faced challenges. The article also touches upon sector trends including aging populations driving demand and pricing pressures from healthcare providers.
Where is Neogen Corporation (NEOG) Headed?
Neogen Corporation (NEOG) is recalling its Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution due to microbial contamination in certain lots, particularly after adverse events were reported in horses. Despite this, the company reported Q2 2026 revenue of $224.7 million, a 2.8% decrease year-over-year, with a net loss of $15.9 million but an adjusted net income of $22.6 million. The article mentions that while NEOG is a recognized pet stock by hedge funds, some AI stocks are seen as having greater growth potential.
Where is Neogen Corporation (NEOG) Headed?
Neogen Corporation (NEOG) is navigating challenges, including a voluntary recall of its Neogen®Vet HYCOAT® product due to microbial contamination, which led to adverse events in horses. Concurrently, the company reported a slight revenue decrease in fiscal Q2 2026 but saw core growth. Despite these issues, the article notes Neogen's recognition as a top pet stock by hedge funds, while suggesting that certain AI stocks might offer greater upside potential.
CenterBook Partners LP Has $3.33 Million Stock Position in Neogen Corporation $NEOG
CenterBook Partners LP significantly reduced its stake in Neogen Corporation (NASDAQ:NEOG) by 55.4% in Q3, now holding 583,007 shares valued at $3.33 million. Despite this, institutional investors collectively own 96.73% of NEOG, with major increases from Vanguard Group Inc. and new stakes from firms like ING Groep NV. Analyst sentiment for Neogen is mixed, with an average "Hold" rating and a target price of $10.67, even as the company recently exceeded earnings estimates.
Neogen stock hits 52-week high at 11.16 USD
Neogen Corporation's stock has reached a new 52-week high of $11.16, reflecting robust market performance with a 98.38% return over six months and attracting investor confidence. Despite not being profitable in the last twelve months, the company is expected to become profitable this year and recently surpassed earnings and revenue expectations in its Q2 FY2026 report. Analysts have raised price targets, highlighting the strong performance of its Food Safety segment as a key growth driver.
Nassif Mikheal, CEO of Neogen, buys $251 in Neog stock
Neogen CEO Nassif Mikheal recently purchased 23 shares of common stock for $251, with the shares now indirectly owned by his son. This director transaction follows Neogen's strong Q2 2026 financial results, which surpassed earnings and revenue expectations, leading to reiterated positive ratings from analysts and an increased price target from Guggenheim.
Nassif Mikheal, CEO of Neogen, buys $251 in Neog stock
Neogen CEO Nassif Mikheal purchased 23 shares of NEOG stock for $251 on February 17, 2026, increasing his indirect holdings to 704 shares through his son's ownership. This transaction follows Neogen's strong Q2 fiscal year 2026 results, which surpassed earnings expectations and led to raised company guidance and positive analyst reactions from William Blair and Guggenheim.
Neogen Corporation (NASDAQ:NEOG) Short Interest Down 15.8% in January
Neogen Corporation (NASDAQ:NEOG) experienced a 15.8% decrease in short interest in January, totaling 11,865,302 shares, representing approximately 5.5% of its shares sold short. Major institutional investors, particularly Goldman Sachs, increased their stakes, while the company reported better-than-expected Q1 earnings but a significant negative net margin. Analysts currently hold a "Hold" consensus rating with an average target price of $10.67.
Neogen (NASDAQ:NEOG) Upgraded at Wall Street Zen
Wall Street Zen upgraded Neogen (NASDAQ:NEOG) from a "hold" to a "buy" rating on Saturday, February 14, 2026. While the company recently beat earnings estimates with EPS of $0.10 and revenue of $224.7M, it remains unprofitable. The stock currently trades around $10.94, with an average analyst consensus rating of "Hold" and a price target of $10.67.
